On February 12, the White House released its Fiscal Year (FY) 2019 budget proposal, which included several provisions and budget changes of interest to the cancer community. While the proposal is not binding, it does provide a view into some of the Administration’s goals and budget priorities for the year.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
Robin Zon, MD, FACP, FASCO, a medical oncologist at Michiana Hematology Oncology and last year’s ASCO Advocate of the Year, joined ASCO CEO Dr. Clifford Hudis this month to discuss Congressional advocacy and the role it plays in shaping cancer-related policies.
Congress passed the “Bipartisan Budget Act of 2018,” which funds the federal government through March 23, 2018, raises the federal budget caps for the next two years, and addresses several policies of importance to the cancer community.
ASCO applauds a provision in the continuing resolution (CR) passed by the House of Representatives yesterday that will ensure that payment adjustments under the Merit-based Incentive Payment System (MIPS) are not applied to Medicare Part B drug reimbursement. ASCO has strongly advocated for this change since the release of a proposed Quality Payment Program rule by the Centers for Medicare and Medicaid Services in June of 2017
On January 22, the U.S. Senate and U.S. House of Representatives voted to pass a short-term Continuing Resolution (CR) to keep the federal government funded through February 8, 2018. The CR, which President Trump signed into law, ends a three-day federal government shutdown and keeps funding levels flat for federal agencies, including the National Institutes of Health (NIH) and the National Cancer Institute (NCI).